In “Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments”, Tripathi et al study the specificity of 3 different antibodies against
atypical chemokine receptor 3 (ACKR3). The specificity of the antibodies was tested by flow cytometry using human vascular smooth muscle cell. Here, a fluorescent signal was measured when treated with siRNA specific for AKCR3 (Human CXCR7 (57007) (E-013212-00-0050)) and compared with the fluorescent signal from cells treated with non-targeting RNA.
When using this antibody, a 66% reduction in fluorescence was observed.
On October 3, 2018 Simon Molgaard wrote:
In “Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments”, Tripathi et al study the specificity of 3 different antibodies against
atypical chemokine receptor 3 (ACKR3). The specificity of the antibodies was tested by flow cytometry using human vascular smooth muscle cell. Here, a fluorescent signal was measured when treated with siRNA specific for AKCR3 (Human CXCR7 (57007) (E-013212-00-0050)) and compared with the fluorescent signal from cells treated with non-targeting RNA.
When using this antibody, a 66% reduction in fluorescence was observed.
See full description in the article:
https://www.ncbi.nlm.nih.gov/pubmed/26660071